Savior Lifetec Corp is engaged in the research, development, design, manufacture, and sale of carbapenem generics, injection generics, controlled-release generics, development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms of the aforementioned products. The company also provides medicine manufacturer technology and services. The company geographically operates in four regions such as the Americas, Asia, Taiwan, and Europe.
2004
312
LTM Revenue n/a
LTM EBITDA n/a
$103M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Savior Lifetec has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Savior Lifetec achieved revenue of $36.8M and an EBITDA of $9.5M.
Savior Lifetec expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Savior Lifetec valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $31.7M | $36.8M | XXX | XXX | XXX |
Gross Profit | $4.0M | $6.7M | XXX | XXX | XXX |
Gross Margin | 12% | 18% | XXX | XXX | XXX |
EBITDA | $6.6M | $9.5M | XXX | XXX | XXX |
EBITDA Margin | 21% | 26% | XXX | XXX | XXX |
Net Profit | $1.1M | $0.9M | XXX | XXX | XXX |
Net Margin | 3% | 2% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Savior Lifetec's stock price is TWD 17 (or $1).
Savior Lifetec has current market cap of TWD 5.3B (or $161M), and EV of TWD 3.4B (or $103M).
See Savior Lifetec trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$103M | $161M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Savior Lifetec has market cap of $161M and EV of $103M.
Savior Lifetec's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Savior Lifetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Savior Lifetec and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $103M | XXX | XXX | XXX |
EV/Revenue | 2.8x | XXX | XXX | XXX |
EV/EBITDA | 10.9x | XXX | XXX | XXX |
P/E | 29.3x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 8.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSavior Lifetec's NTM/LTM revenue growth is n/a
Savior Lifetec's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $22K for the same period.
Over next 12 months, Savior Lifetec's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Savior Lifetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Savior Lifetec and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 16% | XXX | XXX | XXX | XXX |
EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
EBITDA Growth | 43% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $22K | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
Opex to Revenue | 19% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Savior Lifetec acquired XXX companies to date.
Last acquisition by Savior Lifetec was XXXXXXXX, XXXXX XXXXX XXXXXX . Savior Lifetec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Savior Lifetec founded? | Savior Lifetec was founded in 2004. |
Where is Savior Lifetec headquartered? | Savior Lifetec is headquartered in Taiwan. |
How many employees does Savior Lifetec have? | As of today, Savior Lifetec has 312 employees. |
Is Savior Lifetec publicy listed? | Yes, Savior Lifetec is a public company listed on ROCO. |
What is the stock symbol of Savior Lifetec? | Savior Lifetec trades under 4167 ticker. |
When did Savior Lifetec go public? | Savior Lifetec went public in 2015. |
Who are competitors of Savior Lifetec? | Similar companies to Savior Lifetec include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
What is the current market cap of Savior Lifetec? | Savior Lifetec's current market cap is $161M |
What is the current revenue growth of Savior Lifetec? | Savior Lifetec revenue growth between 2023 and 2024 was 16%. |
Is Savior Lifetec profitable? | Yes, Savior Lifetec is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.